Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

It has been about a month since the last earnings report for SurModics (SRDX). Shares have added about 6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is SurModics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended downward during the past month.The consensus estimate has shifted -2050% due to these changes.VGM ScoresCurrently, SurModics has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise SurModics has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.Performance of an Industry PlayerSurModics belongs to the Zacks Medical - Products industry. Another stock from the same industry, Boston Scientific (BSX), has gained 1.3% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.Boston Scientific reported revenues of $4.66 billion in the last reported quarter, representing a year-over-year change of +20.9%. EPS of $0.75 for the same period compares with $0.56 a year ago.For the current quarter, Boston Scientific is expected to post earnings of $0.72 per share, indicating a change of +16.1% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.Boston Scientific has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Surmodics, Inc. (SRDX): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks